Sichuan Kelun Pharmaceutical Co Ltd (002422)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Sichuan Kelun Pharmaceutical Co Ltd (002422) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013342
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sichuan Kelun Pharmaceutical Co Ltd (Kelun) is a pharmaceutical company that manufactures and distributes IV Solutions. The company’s products include mannitol injection, glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’s injection, compound amino acid injection, alanyl glutamine injection, fructose injection, fructose and sodium chloride injection, compound amino acids, fat emulsion injection, vitamin c and glucose injection, vitamin c and sodium chloride injection, kang fu xin solution and lafutidine capsules. It also offers products to serve parenteral nutrition, digestive system, cardiovascular, antipsychotic, respiratory system, anti-pathogenic microorganisms, and APIs and intermediates. Kelun is headquartered in Chengdu, China.

Sichuan Kelun Pharmaceutical Co Ltd (002422) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Debt Offering 11
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 11
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 12
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 13
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 14
Sichuan Kelun Pharma Plans to Raise up to USD269.5 Million in Public Offering of Bonds 15
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 16
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 17
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 18
Acquisition 19
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 19
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 20
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 21
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 22
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 23
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 24
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 25
Sichuan Kelun Pharma Completes Acquisition of 80% Stake in Guilin Dahua Pharma for USD21.9 Million 26
Sichuan Kelun To Acquire 80% Stake In Gui Lin Dahua Pharma 27
Sichuan Kelun Pharmaceutical Co Ltd – Key Competitors 28
Sichuan Kelun Pharmaceutical Co Ltd – Key Employees 29
Sichuan Kelun Pharmaceutical Co Ltd – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sichuan Kelun Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 11
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 12
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 13
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 14
Sichuan Kelun Pharma Plans to Raise up to USD269.5 Million in Public Offering of Bonds 15
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 16
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 17
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 18
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 19
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 20
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 21
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 22
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 23
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 24
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 25
Sichuan Kelun Pharma Completes Acquisition of 80% Stake in Guilin Dahua Pharma for USD21.9 Million 26
Sichuan Kelun To Acquire 80% Stake In Gui Lin Dahua Pharma 27
Sichuan Kelun Pharmaceutical Co Ltd, Key Competitors 28
Sichuan Kelun Pharmaceutical Co Ltd, Key Employees 29
Sichuan Kelun Pharmaceutical Co Ltd, Subsidiaries 30

★海外企業調査レポート[Sichuan Kelun Pharmaceutical Co Ltd (002422)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SolaCom Technologies, Inc.:企業の戦略・SWOT・財務情報
    SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • A-Cap Energy Ltd (ACB):企業の財務・戦略的SWOT分析
    Summary A-Cap Energy Ltd (A-Cap) is a mineral resources development company that acquires, explores, and develops mineral resource properties across Australia. It explores for coal and uranium deposits. Its projects include Letlhakane uranium project, the Mea coal project, and Foley coal project. A- …
  • SpectraCure AB:製薬・医療:M&Aディール及び事業提携情報
    Summary SpectraCure AB (SpectraCure) is a provider of cancer treatment solutions that offers medical device systems containing laser light sources and photoreactive drugs. The company develops and therapy system, commercializes photodynamic with IDOSE for tumors. It provides IDOSE platform which all …
  • Abercrombie & Fitch Co:企業の戦略・SWOT・財務分析
    Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Steel Reef Infrastructure Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Steel Reef Infrastructure Corp (Steel Reef Infrastructure) is a mid-stream company that offers long-term returns through investments in small to midsized infrastructure with focus on the Western Canadian Sedimentary Basin. The company offers services such as construction, operation, manageme …
  • Arkansas Electric Cooperative Corporation:企業の発電所・SWOT分析2018
    Arkansas Electric Cooperative Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inform …
  • DCP Midstream Partners, LP:企業の戦略・SWOT・財務情報
    DCP Midstream Partners, LP - Strategy, SWOT and Corporate Finance Report Summary DCP Midstream Partners, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rosinter Restaurants Holding Ojsc
    Rosinter Restaurants Holding Ojsc - Strategy, SWOT and Corporate Finance Report Summary Rosinter Restaurants Holding Ojsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cedar Fair, L.P.:企業の戦略・SWOT・財務情報
    Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report Summary Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Saskatchewan Power Corp:企業の戦略的SWOT分析
    Saskatchewan Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • BASF SE (BAS):電力:M&Aディール及び事業提携情報
    Summary BASF SE (BASF) is a chemical company, which carries out research and development (R&D), production, marketing and sales of chemicals, plastics, crop protection products, and performance products. Its product line comprises solvents, adhesives, surfactant, organic chemicals, fuel additives, e …
  • CBRE Group, Inc.:企業の戦略・SWOT・財務分析
    CBRE Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary CBRE Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • NWS Holdings Limited:企業の戦略・SWOT・財務情報
    NWS Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary NWS Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • HitGen LTD:企業のM&A・事業提携・投資動向
    HitGen LTD - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HitGen LTD Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Heroux-Devtek Inc:企業の戦略・SWOT・財務分析
    Heroux-Devtek Inc - Strategy, SWOT and Corporate Finance Report Summary Heroux-Devtek Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • JenaValve Technology Inc:医療機器:M&Aディール及び事業提携情報
    Summary JenaValve Technology Inc (JenaValve Technology), a subsidiary of JenaValve Technology GmbH, is a medical device company that develops and manufactures transcatheter aortic valve replacement (TAVR) systems for transapical and transfemoral implantation. The company’s TAVR system is an investig …
  • Oki Electric Industry Co., Ltd.:企業の戦略・SWOT・財務情報
    Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Petrosibir AB (PSIB B):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrosibir AB (Petrosibir), formerly Shelton Petroleum AB is an oil and gas company. The company offers exploration and development of oil and gas assets and the resource-rich basins in Russia and Ukraine. It holds Ayazovskoye production license and Rustamovskoye exploration license that cov …
  • Canadian Solar Inc (CSIQ):企業の財務・戦略的SWOT分析
    Canadian Solar Inc (CSIQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Histocell SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Histocell SL (Histocell), a subsidiary of Noray Biosciences Group, is a biopharmaceutical company that develops cell therapy and tissue engineering products for regenerative medicine. The company provides Wharton Gel Complex, medical devices, contract manufacturing and cell therapy programs, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆